Mr. Ring has served as chairman and CEO of Bard since Aug. 8, 2003. He joined Bard in June 1992 and has served in many leadership roles including corporate vice president of Human Resources, group vice president of Bard International, group president for Coronary Vascular Products and group president for Electrophysiology and Peripheral Vascular Products. Prior to joining Bard, Mr. Ring worked for Abbott Laboratories and The General Motors Corporation.
In addition to the Bard board of directors, Mr. Ring is a director of Quest Diagnostics Incorporated, a trustee for the New Jersey Health Foundation (NJHF), and a board member for the Advanced Medical Technology Association (AdvaMed), the National Association of Manufacturers (NAM) and the Healthcare Leadership Council. He also currently serves on the Cornell University Council and is a former Chairman of the Board of Trustees of the HealthCare Institute of New Jersey (HINJ).
Mr. Ring earned a bachelor of science degree in Industrial and Labor Relations from Cornell University.
David F. Melcher has been president and CEO of the Aerospace Industries Association (AIA) since 2015. Prior to AIA, Mr. Melcher was CEO and president of Exelis Inc., a spinoff of ITT Corporation. Mr. Melcher joined ITT in 2008 after a 32-year career with the U.S. Army until his retirement as a Lieutenant General.
In addition to being a director for Bard, Mr. Melcher is a member of the Federal Aviation Administration’s NextGen Advisory Committee, providing advice on policy-level issues for the nation’s aviation modernization. He is a recipient of the Army’s Distinguished Service Medal and the Association of the U.S. Army John W. Dixon award for contributions to the defense industry.
Mr. Melcher holds a bachelor of science degree in civil engineering from the U.S. Military Academy at West Point and two master’s degrees, one in business administration from Harvard University and the other in public administration from Shippensburg University.
BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures, and support the management of diabetes. The company partners with organizations around the world to address some of the most challenging global health issues. BD has nearly 50,000 associates across 50 countries who work in close collaboration with customers and partners to help enhance outcomes, lower health care delivery costs, increase efficiencies, improve health care safety and expand access to health. For more information on BD, please visit bd.com.
Powered by WPeMatico